Median progression-free survival was 3.7 months, with 44.4% of patients being progression free at 6 months and 32.3% at 12 ...

AstraZeneca Vietnam has been honoured in the Outstanding CSR Activities category at the 2025 Top 50 Corporate Sustainability ...

AstraZeneca Plc (NASDAQ:AZN) released high-level results from the Cardiac Amyloid Reaching for Extended Survival (CARES) ...

An antibody being developed by AstraZeneca for the treatment of light chain (AL) amyloidosis has failed to move the needle in ...

With the company's market capitalization at Rs 2,292.62 Crore, this dividend payout reflects AstraZeneca's commitment to returning value to its shareholders.

ABBV's oncology sales might have dipped in Q2 as gains from newer drugs face pressure from Imbruvica's ongoing decline.

Anselamimab, which AstraZeneca acquired via Caelum Biosciences, missed its primary goal in two late-stage trials, but appeared to have some benefit in a subgroup of patients.

US pharma major AstraZeneca today released high-level results from the Cardiac Amyloid Reaching for Extended Survival (CARES) ...

The plan – backed with a £2 billion ($2.68 billion) funding pledge – revolves around three overarching objectives, namely ...

The antibody anselamimab, which AstraZeneca picked up in its 2021 purchase of Caelum Biosciences, failed to improve survival and reduce hospitalizations, but the company sees promise in data from an ...

AstraZeneca’s CARES phase III clinical programme of anselamimab in light chain amyloidosis fails to meet primary endpoint: Cambridge, UK Thursday, July 17, 2025, 09:00 Hrs [IST] ...

Donald Trump has threatened new tariffs on medicines within weeks as he steps up demands for drugmakers to move factories to ...